Filing Flows › Dianthus Therapeutics (DNTH) › Q4 2024
Dianthus Therapeutics (DNTH) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 11, 2025
Dianthus Therapeutics (DNTH) reported revenue of $1.3M for the fourth quarter 2024 (Q4 2024), +190% from a year earlier and -39% from the quarter before.
Dianthus Therapeutics, Q4 2024: revenue $1.3M (+190% year over year), net loss $28.4M, operating cash flow −$27.4M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.3M | -39% | +190% |
| Operating profit | −$31.9M | — | — |
| Net earnings | −$28.4M | — | — |
| Operating cash flow | −$27.4M | — | — |
What changed
Revenue was $1.3M in Q4 2024, up 190% year over year and down 39% from the previous quarter.
Operating costs exceeded revenue by $31.9M, an operating margin of -2406.9%. Total costs grew 148% against revenue growth of 190%. The fastest-growing cost line was Research & development (+201%). The quarter ended with a net loss of $28.4M, wider than the previous quarter's $25.2M loss.
Operating cash flow was −$27.4M. Non-cash charges added back $26K of depreciation and $3.9M of share-based compensation. Working capital and other items used $2.9M. Capital expenditures of $31K exceeded it, leaving free cash flow of −$27.5M.
Questions
What was Dianthus Therapeutics' revenue in the fourth quarter 2024?
Dianthus Therapeutics (DNTH) reported revenue of $1.3M for the fourth quarter 2024 (Q4 2024), +190% from a year earlier and -39% from the quarter before.